Psychiatric and Neurodevelopmental Disorders
Psychoses and autism spectrum disorder are central areas of interest, with attention to biological factors linked to treatment response and core symptom expression.
- Schizophrenia and psychosis
- Autism spectrum disorder
- Genetic polymorphisms in CYP1A2, MDR1, 5HT2A, 5HT2C, HDAC3, and HDAC4
Research activity in this domain includes pharmacogenetic and microbiome-related approaches to psychiatric symptoms and neurodevelopmental phenotypes.
Pediatric Oncology
The sponsor supports studies in progressive, recurrent, and metastatic high-risk paediatric malignancies, including immunotherapy-based strategies.
- High-risk paediatric tumors
- Dendritic cell-based antitumor therapy
- Interleukin-12-producing cellular approaches
This area also includes safety-focused clinical research in children, adolescents, and young adults with advanced cancer.
Dermatologic and Rare Genetic Skin Disease
Clinical research extends to epidermolysis bullosa congenita, with emphasis on cell-based treatment concepts for severe inherited skin fragility disorders.
- Epidermolysis bullosa
- Mesenchymal stromal cells
- Intradermal administration
These studies address safety and therapeutic potential in a rare disease setting with limited treatment options.
Neonatal and Perinatal Medicine
Another focus is primary apnea in preterm newborns, with interest in respiratory support outcomes and caffeine-related neonatal care.
- Preterm newborns
- Invasive respiratory support
- Caffeine in neonatal treatment
Work in this field reflects a clinical interest in improving respiratory stability and early-life outcomes in vulnerable infants.
Hematology and Treatment Discontinuation Research
Studies in chronic myeloid leukemia examine treatment withdrawal after deep remission, with emphasis on maintaining disease control after tyrosine kinase inhibitor reduction.
- Chronic myeloid leukemia
- Deep molecular remission
- Tyrosine kinase inhibitor discontinuation
This area is closely linked to long-term management strategies in hematologic malignancy.
